You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
天士力(600535.SH):吲達帕胺片通過仿製藥一致性評價
格隆匯 01-14 17:18

格隆匯1月14日丨天士力(600535.SH)公佈,近日,公司控股子公司天津天士力(遼寧)製藥有限責任公司(以下簡稱“遼寧天士力”)收到國家藥品監督管理局頒發的關於吲達帕胺片2.5mg規格的《藥品補充申請批件》(批件號:2020B02108),該藥品通過仿製藥一致性評價。

吲達帕胺片為磺胺類利尿劑,具有利尿和鈣拮抗作用,是一種強效、長效的降壓藥,臨牀上主要用於治療原發性高血壓。根據PDB藥物綜合數據庫數據顯示,吲達帕胺片2018年在全球銷售額為8.19億美元,同比上漲3.80%。經查詢,中國境內已上市的吲達帕胺片生產企業主要有天津力生製藥股份有限公司、施維雅(天津)製藥有限公司(原研)等。截至公告日,遼寧天士力針對該藥品一致性評價已投入研發費用約為748.07萬元人民幣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account